Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
[Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists]

M. Holická, J. Vysloužil, K. Kubová, J. Muselík, D. Vetchý

. 2021 ; 115 (10) : 516-523.

Jazyk čeština Země Česko

Typ dokumentu přehledy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22022583

Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropin-releasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flare-up phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.

Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22022583
003      
CZ-PrNML
005      
20221114141515.0
007      
ta
008      
220929s2021 xr f 000 0|cze||
009      
AR
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Holická, Martina $7 xx0260799 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
245    10
$a Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté / $c M. Holická, J. Vysloužil, K. Kubová, J. Muselík, D. Vetchý
246    31
$a Gonadoliberin (gonadotropin-releasing hormone), its agonists and antagonists
504    __
$a Literatura
520    9_
$a Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropin-releasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flare-up phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
650    17
$a hormon uvolňující gonadotropiny $x agonisté $x antagonisté a inhibitory $x aplikace a dávkování $x biosyntéza $x chemie $x farmakologie $x fyziologie $x klasifikace $7 D007987 $2 czmesh
650    _7
$a veterinární léky $x aplikace a dávkování $x klasifikace $7 D019155 $2 czmesh
655    _7
$a přehledy $7 D016454 $2 czmesh
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Vysloužil, Jakub $7 xx0231488 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
700    1_
$a Kubová, Kateřina $7 xx0231489 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
700    1_
$a Muselík, Jan $7 xx0100243 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
700    1_
$a Vetchý, David, $d 1972- $7 mzk2006368163 $u Ústav farmaceutické technologie, Farmaceutická fakulta, Masarykova univerzita, Brno
773    0_
$t Chemické listy $x 0009-2770 $g Roč. 115, č. 10 (2021), s. 516-523 $w MED00011010
856    41
$u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3933/3844 $y plný text volně přístupný
910    __
$a ABA008 $b B 1918 $c 395 $y p $z 0
990    __
$a 20220929104939 $b ABA008
991    __
$a 20221114141512 $b ABA008
999    __
$a ok $b bmc $g 1842929 $s 1173868
BAS    __
$a 3
BMC    __
$a 2021 $b 115 $c 10 $d 516-523 $i 0009-2770 $m Chemické listy $x MED00011010
LZP    __
$c NLK189 $d 20221114 $a NLK 2022-17/kv

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...